Degrading the anaplastic lymphoma kinase protein to treat paediatric cancers
Dr Lizzie Tucker will assess a new type of treatment to fight ALK-driven childhood cancers like neuroblastoma.
We have been funding expert research since 2016, aiming to ensure that every child and young person has a safe and effective treatment for their cancer, and that they can live long and happy lives post-treatment.
Dr Lizzie Tucker will assess a new type of treatment to fight ALK-driven childhood cancers like neuroblastoma.
Professor Suzanne Turner will investigate the behaviour of individual lymphoma cells in order to find out why treatments fail.
Dr Maria Teresa Esposito hopes to learn more about a gene called SET in leukaemia and will test the best medicines to fight it.
Dr Shelby Barnett and Dr Geoff Shenton will monitor crucial drug levels in patients' blood in order to improve CAR T therapy protocols.
Prof Jonathan Bond and Dr Marie-Claire Fitzgerald aim to find a treatment that can exploit a key weakness of acute myeloid leukaemia.
Dr Lucia Cottone at University College London hopes to understand how osteosarcoma cells become resistant to chemotherapy, which has a big impact on patient survival.
It is particularly difficult to treat some groups of childhood cancer patients, especially infants in their first weeks of life. This application is to fund this rapidly developing research programme for two years, involving the treatment of 150-200.
Creating an immunotherapy that can be delivered to patients more quickly and cost-effectively.
Looking at how cancer cells alter the scaffolding inside the body that organises cells in order to spread and make new tumours.